Caribou Biosciences (NASDAQ:CRBU) Posts Earnings Results, Beats Estimates By $0.05 EPS

Caribou Biosciences (NASDAQ:CRBU) posted its earnings results on Thursday. The company reported ($0.28) earnings per share for the quarter, topping the consensus estimate of ($0.33) by $0.05, FiscalAI reports. The firm had revenue of $3.94 million during the quarter, compared to analysts’ expectations of $1.96 million. Caribou Biosciences had a negative return on equity of 69.85% and a negative net margin of 1,690.45%.

Caribou Biosciences Trading Down 5.0%

Shares of CRBU traded down $0.09 during mid-day trading on Thursday, hitting $1.71. 1,078,171 shares of the company’s stock were exchanged, compared to its average volume of 1,266,392. Caribou Biosciences has a fifty-two week low of $0.66 and a fifty-two week high of $3.54. The business’s 50 day moving average is $1.64 and its two-hundred day moving average is $1.90. The firm has a market capitalization of $159.83 million, a P/E ratio of -1.01 and a beta of 2.54.

Institutional Inflows and Outflows

A number of institutional investors have recently modified their holdings of CRBU. Creative Planning acquired a new stake in shares of Caribou Biosciences during the second quarter worth $25,000. Hudson Bay Capital Management LP acquired a new stake in shares of Caribou Biosciences in the 2nd quarter worth $30,000. Russell Investments Group Ltd. boosted its holdings in shares of Caribou Biosciences by 80.0% in the fourth quarter. Russell Investments Group Ltd. now owns 24,347 shares of the company’s stock valued at $39,000 after acquiring an additional 10,824 shares in the last quarter. Invesco Ltd. increased its stake in shares of Caribou Biosciences by 187.2% during the fourth quarter. Invesco Ltd. now owns 35,063 shares of the company’s stock worth $56,000 after acquiring an additional 22,856 shares during the period. Finally, Man Group plc acquired a new stake in Caribou Biosciences in the fourth quarter valued at about $58,000. Institutional investors and hedge funds own 77.51% of the company’s stock.

Analyst Ratings Changes

A number of analysts have weighed in on CRBU shares. Weiss Ratings reissued a “sell (d-)” rating on shares of Caribou Biosciences in a report on Wednesday, January 21st. HC Wainwright lifted their price target on shares of Caribou Biosciences from $3.00 to $9.00 and gave the stock a “buy” rating in a research note on Wednesday, November 5th. Two research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, the company presently has a consensus rating of “Hold” and a consensus price target of $8.00.

About Caribou Biosciences

Caribou Biosciences, Inc is a clinical-stage biopharmaceutical company that leverages its proprietary CRISPR-Cas gene-editing platform to develop transformative cell therapies and in vivo treatments for a range of cancers and genetic diseases. The company’s core technology enables precise modification of cellular genomes, allowing the design of engineered T-cell and NK-cell therapies aimed at improving safety, efficacy and persistence in patients with hematologic and solid tumor malignancies. Alongside its oncology portfolio, Caribou is advancing in vivo editing programs targeting monogenic disorders, with initiatives in areas such as Duchenne muscular dystrophy and familial amyloidosis.

Established in 2011 and headquartered in Berkeley, California, Caribou Biosciences was co-founded by Nobel laureate Jennifer Doudna, one of the pioneers of CRISPR gene-editing technology.